Ralph Turner
Obstetrics & Gynecology · Tyler, TXNPI 1013950997
Payments from drug & device makers
Across 126 payments — averaging $430.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$31K
- Astellas Pharma US Inc$12K
- Merck$10K
- Mayne Pharma Commercial LLC$291
- AbbVie$271
- Astellas Pharma Global Development$122
- plus $626 from 18 others
What the payments were for
- Consulting fees$110%
- Speaking & faculty fees$51,26695%
- Travel & lodging$9242%
- Food & beverage$1,9934%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 39 | $30,834 |
| Astellas Pharma US Inc | 14 | $11,598 |
| Merck | 17 | $10,453 |
| Mayne Pharma Commercial LLC | 3 | $291 |
| AbbVie(2 entities) | 16 | $271 |
| Astellas Pharma Global Development | 1 | $122 |
| Sage Therapeutics, LLC | 7 | $109 |
| Pfizer | 5 | $78 |
| Exeltis, USA Inc. | 4 | $74 |
| Bayer | 3 | $54 |
| Aesculap, Inc. | 1 | $40 |
| Exact Sciences | 2 | $39 |
| Axonics, Inc. | 2 | $37 |
| AMAG Pharmaceuticals, Inc. | 2 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Duchesnay USA Incorporated | 1 | $21 |
| Cumberland Pharmaceuticals, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Lupin Inc. | 1 | $14 |
| Minerva Surgical, Inc | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Evofem Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,194 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 16 | $9,276 |
| Estradiol | 43 | $2,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $78 | $9,27616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Tyler
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- John Paul RobertsPlano$4.9M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
- Dawnette PepplerArlington$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.